Helicobacter pylori infection is associated with an increased risk of Parkinson's disease: A population-based retrospective cohort study.

BACKGROUND: Several studies have evaluated the association of Parkinson's disease with Helicobacter pylori (HP) infection, although no cohort studies have evaluated this association among the general population. OBJECTIVE: This study aimed to investigate the risk of Parkinson's disease after HP infection in the general Taiwanese population. METHODS: This study of Taiwanese health insurance data (2000-2012) evaluated 9105 cases of HP infection and 9105 controls matched with propensity scoring. Univariate and multivariate Cox proportional hazards regression models were used to assess the risk of subsequent Parkinson's disease. RESULTS: We observed 64 cases of Parkinson's disease in the HP infection group (1.7/1000 person-years), and 25 cases in the control group (0.7/1000 person-years). Overall, there was a significantly higher risk of Parkinson's disease in the HP infection group (adjusted hazard ratio [aHR]: 2.29, 95% confidence interval [CI]: 1.44-3.66). HP infection was significantly associated with an increased risk of Parkinson's disease among individuals who were ≥60 years old (aHR: 2.53, 95% CI: 1.47-4.35), but not among those <60 years old (aHR: 1.86, 95% CI: 0.69-4.98). Furthermore, HP infection was associated with an increased risk of Parkinson's disease among both men (aHR: 2.14, 95% CI: 1.15-3.96) and women (aHR: 2.84, 95% CI: 1.37-5.89). Nonetheless, eradication therapy was not significantly associated with the risk of Parkinson's disease (aHR: 1.07, 95% CI: 0.63-1.82). CONCLUSION: Although HP infection was associated with an increased risk of Parkinson's disease, eradication therapy did not ameliorate this association. Further research is needed to explore the underlying biological mechanisms.

Increased risk of peripheral arterial occlusive disease in patients with Bell's palsy using population data.

OBJECTIVE: This population-based cohort study investigated the risk of developing peripheral arterial occlusive disease (PAOD) in patients with Bell's palsy. METHODS: We used longitudinal claims data of health insurance of Taiwan to identify 5,152 patients with Bell's palsy newly diagnosed in 2000-2010 and a control cohort of 20,608 patients without Bell's palsy matched by propensity score. Incidence and hazard ratio (HR) of PAOD were assessed by the end of 2013. RESULTS: The incidence of PAOD was approximately 1.5 times greater in the Bell's palsy group than in the non-Bell's palsy controls (7.75 vs. 4.99 per 1000 person-years). The Cox proportional hazards regression analysis measured adjusted HR was 1.54 (95% confidence interval (CI) = 1.35-1.76) for the Bell's palsy group compared to the non-Bell's palsy group, after adjusting for sex, age, occupation, income and comorbidities. Men were at higher risk of PAOD than women in the Bell's palsy group, but not in the controls. The incidence of PAOD increased with age in both groups, but the Bell's palsy group to control group HR of PAOD decreased as age increased. The systemic steroid treatment reduced 13% of PAOD hazard for Bell's palsy patients, compared to those without the treatment, but not significant. CONCLUSIONS: Bell's palsy appears to be associated with an increased risk of developing PAOD. Further pathophysiologic, histopathology and immunologic research is required to explore the underlying biologic mechanism.

Epidemiology and prognostic factors of inpatient mortality of Guillain-Barré syndrome: A nationwide population study over 14years in Asian country.

OBJECTIVE: The present study aimed to evaluate the characteristics of inpatient mortality from Guillain-Barré syndrome (GBS), which is a rare and potentially life-threatening polyradiculoneuropathy, in an Asian country, as there are few big-data studies regarding this topic. METHODS: We obtained data regarding patients with GBS from Taiwan's National Health Insurance Research Database admission records. We identified patients with a discharge diagnosis of GBS during 2000-2013 using the International Classification of Diseases, 9th Revision, Clinical Modification code (357.0), and evaluated their baseline characteristics, clinical complications, and risk factors. RESULTS: We identified 5469 patients with GBS, and the crude incidence of GBS was 1.71 per 100,000 person-years. The inpatient mortality rate was 1.61% (88/5469) and 55 deaths (62.5% of all deaths) occurred before day 19 of the hospitalization (mainly during the progressive phase). The predictors of inpatient mortality included older age, a greater comorbidity burden (especially catastrophic illness), endotracheal intubation, mechanical ventilation, cardiac complications, and systemic infection. In contrast, patients who were admitted to a medical center or Neurology Department exhibited a higher survival rate. CONCLUSIONS: This 14-year nationwide study included the largest analysis of Asian patients with GBS to date, and identified various prognostic factors that predicted inpatient mortality.

Aggravation of hypertriglyceridemia and acute pancreatitis in a bipolar patient treated with quetiapine.

Pancreatitis is a very rare adverse effect of quetiapine treatment, with only 5 cases of quetiapine-associated pancreatitis reported in the English literature to date. Herein, we report one patient who developed severe hypertriglyceridemia (>1000 mg/dL) after quetiapine administration, resulting in acute pancreatitis. An analysis of the underlying pathogenic mechanisms and a review of relevant literature are also presented. Clinicians should be aware of the potentially life-threatening metabolic disturbances and/or pancreatitis associated with quetiapine therapy.